id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-N-0143-1116,FDA,FDA-2009-N-0143,See FDA-2009-N-0143-1017,Supporting & Related Material,,2010-05-28T00:00:00Z,2010,5,,,2012-03-24T19:36:10Z,,0,1,0900006480af0da6
FDA-2009-N-0143-1063,FDA,FDA-2009-N-0143,Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting,Notice,NM-Notice of Meeting,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,2009-11-28T04:59:59Z,2009-11-18T17:39:41Z,E9-27718,0,0,0900006480a58ff2
FDA-2009-N-0143-1061,FDA,FDA-2009-N-0143,Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting; Reopening of Comment Period,Notice,N-Notice,2009-10-19T04:00:00Z,2009,10,2009-10-19T04:00:00Z,2010-10-20T03:59:59Z,2009-10-19T16:11:42Z,E9-25022,0,0,0900006480a44cce
FDA-2009-N-0143-0838,FDA,FDA-2009-N-0143,"Public Meeting Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs, May 27, 2009  - Transcript",Other,TR-Transcript,2009-06-30T04:00:00Z,2009,6,2009-06-30T04:00:00Z,,2013-07-27T22:48:18Z,,0,0,09000064809e6ce5
FDA-2009-N-0143-0839,FDA,FDA-2009-N-0143,"Public Meeting Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs, May 28, 2009 - Transcript",Other,TR-Transcript,2009-06-30T04:00:00Z,2009,6,2009-06-30T04:00:00Z,,2013-07-27T22:48:18Z,,0,0,09000064809e6ce6
FDA-2009-N-0143-0002,FDA,FDA-2009-N-0143,Meetings: Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs,Notice,NM-Notice of Meeting,2009-04-20T04:00:00Z,2009,4,2009-04-20T04:00:00Z,2009-07-01T03:59:59Z,2009-04-20T15:19:31Z,E9-08992,0,0,090000648095e49e
FDA-2009-N-0143-0001,FDA,FDA-2009-N-0143,Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting - Request to Open Docket,Other,ELET-Electronic Letter,2009-03-31T04:00:00Z,2009,3,,,2009-04-20T16:57:54Z,,0,0,0900006480939040